Cultivated protein company Parima has completed the core safety risk assessment stage of Food Standards Australia New Zealand’s (FSANZ) novel food approval process for cultivated meat, becoming the first company outside Australia and New Zealand to reach this point in the FSANZ pathway, and only the second company globally to do so.
“This achievement is again the result of years of hard work by our team”
The assessment covers Parima’s cultivated duck, produced from duck embryonic stem cells isolated from fertilized Pekin duck eggs. According to FSANZ documentation, the production cell line is non-genetically modified and has been fully characterized through genomic and karyotyping analyses to confirm identity and stability. With the core safety review complete, the application now moves to public consultation before a final approval decision.
“This achievement is again the result of years of hard work by our team. We are incredibly grateful to FSANZ for the efficiency of their review process,” Parima said in a LinkedIn statement.
A third jurisdiction enters the pipeline
The FSANZ development follows two Singapore Food Agency approvals secured within the past year: cultivated chicken in October 2025 and cultivated duck in April 2026, the latter making Parima the first cultivated meat company to hold regulatory clearance for two species. The Australia and New Zealand milestone adds a third regulatory jurisdiction to the company’s growing portfolio, with eight active filings across Europe, Asia, and North America also in progress.
The only other company to have passed the FSANZ core safety assessment is Australian cultivated quail producer Vow, which received full FSANZ approval in June 2025 and has since been selling its products in restaurants across Australia.
Parima continued, “Our production platform is now validated across two species and in two distinct jurisdictions, further proving that our products and processes consistently meet the most rigorous safety requirements.”
